Some 1,390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using OpenAI’s “GPT-Rosalind” and Janux debuted a “double-masked” T cell engager.

If confirmed by the Senate, Schwartz could finally fill a void for an agency that’s cycled through multiple leaders over the last year.

The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” ...

The clearance of Filspari in a condition known as FSGS ends a winding regulatory journey and unlocks a revenue opportunity ...

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a ...

Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined the “$30 million club.” ...

The estimated 6,000 women a day who reach menopause experience it differently. Some have debilitating, vasomotor symptoms ...

The combined company will trade on the Nasdaq under the ticker OBX. It has also secured commitments for a private placement ...

Novo intends to “fully integrate” AI capabilities across its operations. Elsewhere, Regeneron made its first foray into ...

After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, ...

The findings, which come amid FDA scrutiny of Foundayo’s safety, will enable Lilly to seek a new clearance in diabetes.

The request, which is part of a just-released approval letter for Foundayo, comes amid an intensifying marketing battle ...